[go: up one dir, main page]

MX2009005043A - Polimorfos de intermedios nicotinicos. - Google Patents

Polimorfos de intermedios nicotinicos.

Info

Publication number
MX2009005043A
MX2009005043A MX2009005043A MX2009005043A MX2009005043A MX 2009005043 A MX2009005043 A MX 2009005043A MX 2009005043 A MX2009005043 A MX 2009005043A MX 2009005043 A MX2009005043 A MX 2009005043A MX 2009005043 A MX2009005043 A MX 2009005043A
Authority
MX
Mexico
Prior art keywords
polymorphs
nicotinic
intermediates
iii
compounds
Prior art date
Application number
MX2009005043A
Other languages
English (en)
Inventor
Douglas J M Allen
Melissa Jean Casteel
David Burns Damon
Travis Lee Houston
Lien Helen Koztecki
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MX2009005043A publication Critical patent/MX2009005043A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan formas cristalinas de los compuestos II, III y IV y procedimientos para producir las mismas. (ver fórmulas).
MX2009005043A 2006-11-09 2007-11-09 Polimorfos de intermedios nicotinicos. MX2009005043A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86507706P 2006-11-09 2006-11-09
US98540607P 2007-11-05 2007-11-05
PCT/US2007/023683 WO2008060487A2 (en) 2006-11-09 2007-11-09 Polymorphs of nicotinic intermediates

Publications (1)

Publication Number Publication Date
MX2009005043A true MX2009005043A (es) 2009-05-25

Family

ID=39204744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005043A MX2009005043A (es) 2006-11-09 2007-11-09 Polimorfos de intermedios nicotinicos.

Country Status (11)

Country Link
US (1) US20100062046A1 (es)
EP (1) EP2086977A2 (es)
JP (1) JP2010527907A (es)
KR (1) KR20090086071A (es)
AU (1) AU2007319951A1 (es)
BR (1) BRPI0718600A2 (es)
CA (1) CA2666327A1 (es)
IL (1) IL197956A0 (es)
MX (1) MX2009005043A (es)
RU (1) RU2009116260A (es)
WO (1) WO2008060487A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
US9155725B2 (en) 2008-02-27 2015-10-13 Hisamitsu Pharmaceutical Co., Inc. Adhesive skin patch and packaged product
WO2009107477A1 (ja) * 2008-02-27 2009-09-03 久光製薬株式会社 貼付製剤
EP2268639A2 (en) 2008-05-22 2011-01-05 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (en) 2008-09-01 2011-06-22 Actavis Group PTC EHF Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
US20120093887A1 (en) 2009-06-10 2012-04-19 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
RU2012102052A (ru) 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
WO2011110954A1 (en) 2010-03-09 2011-09-15 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9814592B1 (pt) * 1997-12-31 2010-06-01 composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento.
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
HRP20030910B1 (hr) * 2001-05-14 2011-11-30 Pfizer Products Inc. Tartaratne soli 5,8,14-triazatetraciklo {10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>}-heksadeka-2(11), 3,5,7,9-pentaena i pripadajućih farmaceutskih spojeva
KR20040008175A (ko) * 2001-05-14 2004-01-28 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로(10.3.1.02,11.04,9)-헥사데카-2(11),3,5,7,9-펜타엔의 시트르산염 및 그의 제약 조성물
DE60209929T2 (de) * 2001-11-29 2006-11-16 Pfizer Products Inc., Groton Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen
EP1523334A2 (en) * 2002-07-18 2005-04-20 Cytos Biotechnology AG Hapten-carrier conjugates and uses thereof
JP2008531540A (ja) 2005-02-24 2008-08-14 ファイザー・プロダクツ・インク 高純度置換キノキサリンの調製
BRPI0709268A2 (pt) 2006-03-27 2011-06-28 Pfizer Prod Inc padrão de vareniclina e controles de impureza

Also Published As

Publication number Publication date
WO2008060487A2 (en) 2008-05-22
KR20090086071A (ko) 2009-08-10
WO2008060487A3 (en) 2008-08-07
CA2666327A1 (en) 2008-05-22
EP2086977A2 (en) 2009-08-12
IL197956A0 (en) 2009-12-24
AU2007319951A1 (en) 2008-05-22
WO2008060487B1 (en) 2008-09-18
RU2009116260A (ru) 2010-11-10
BRPI0718600A2 (pt) 2013-12-10
WO2008060487A8 (en) 2009-05-14
US20100062046A1 (en) 2010-03-11
JP2010527907A (ja) 2010-08-19

Similar Documents

Publication Publication Date Title
MX2009005043A (es) Polimorfos de intermedios nicotinicos.
MX2010002836A (es) Bortezomib y proceso para la produccion del mismo.
SG148142A1 (en) Aryloazol-2-yl cyanoethylamino compunds, method of making and method of using thereof
MY147732A (en) Process for the preparation of 2-substituted-5- (1-alkylthio) alkylpyridines
EA200900793A1 (ru) Способ получения эзетимиба и его производных
MX2009011255A (es) Proceso para preparar capecitabina.
IL203761A (en) Process for Preparation of Compounds 4 - Aminobut - 2 - Anabolic, Intermediate and Initial Compounds
WO2008151170A3 (en) Process for the synthesis of ramelteon and its intermediates
NZ586187A (en) Processes for the synthesis of sinomenine derivatives and their intermediate
IN2012DN01342A (es)
WO2009005647A3 (en) Compounds and process to prepare chiral intermediates for synthesis of paroxetine
MY163214A (en) Synthesis of 2-carboxamide cycloamino urea dervatives
TW200825088A (en) Processes for preparing intermediates of pemetrexed
UA106988C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та необхідні проміжні сполуки магнію
WO2009062659A3 (en) Polymorphs of enantiopure erdosteine
PH12012501153A1 (en) Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
WO2009076948A3 (de) Reduktone zur erzeugung von biogas
EP2359367B8 (en) Process control of tolerance rings
MX2009012593A (es) Nuevos metodos para preparar isofagomina y sus derivados.
WO2007096875A3 (en) Novel polymorphs of montelukast ammonium salts and processes for preparation therefor
WO2009153047A3 (de) Biotechnologische herstellung von acrylsäure
WO2009116081A3 (en) An improved process for the preparation of aprepitant
WO2012035303A3 (en) A novel process for synthesis of ramelteon, and key intermediates for the synthesis of ramelteon
MX2010003056A (es) Polimorfos de valomaciclovir.
WO2010049500A3 (en) A process for the preparation of tadalafil

Legal Events

Date Code Title Description
FA Abandonment or withdrawal